Analysts Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) PT at $11.64

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has been given an average rating of “Buy” by the thirteen ratings firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, ten have given a buy rating and two have issued a strong buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $11.6364.

A number of equities research analysts have issued reports on the stock. Needham & Company LLC lifted their target price on shares of Taysha Gene Therapies from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, March 19th. Chardan Capital reissued a “buy” rating and set a $12.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, March 19th. Truist Financial raised shares of Taysha Gene Therapies to a “strong-buy” rating in a research note on Wednesday, March 25th. Raymond James Financial reissued a “strong-buy” rating and set a $13.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, January 6th. Finally, Wells Fargo & Company raised their price target on Taysha Gene Therapies from $8.00 to $11.00 and gave the stock an “overweight” rating in a research note on Monday, January 5th.

Taysha Gene Therapies Stock Performance

NASDAQ TSHA opened at $6.43 on Wednesday. Taysha Gene Therapies has a twelve month low of $1.22 and a twelve month high of $6.50. The company has a debt-to-equity ratio of 0.20, a quick ratio of 12.23 and a current ratio of 12.23. The stock has a market cap of $1.85 billion, a price-to-earnings ratio of -18.91 and a beta of 1.10. The firm’s 50 day moving average price is $4.63 and its two-hundred day moving average price is $4.79.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings data on Thursday, March 19th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.03. The firm had revenue of $5.49 million for the quarter, compared to analysts’ expectations of $1.89 million. Equities analysts anticipate that Taysha Gene Therapies will post -0.35 EPS for the current year.

Insider Transactions at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 200,000 shares of the firm’s stock in a transaction on Friday, April 10th. The shares were sold at an average price of $4.46, for a total transaction of $892,000.00. Following the transaction, the insider owned 1,136,410 shares in the company, valued at approximately $5,068,388.60. This trade represents a 14.97% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Kamran Alam sold 23,849 shares of the firm’s stock in a transaction on Monday, January 26th. The shares were sold at an average price of $4.61, for a total transaction of $109,943.89. Following the transaction, the chief financial officer owned 1,443,786 shares in the company, valued at $6,655,853.46. This represents a 1.62% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 598,623 shares of company stock valued at $2,772,188 in the last three months. Corporate insiders own 3.78% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of TSHA. AQR Capital Management LLC raised its holdings in shares of Taysha Gene Therapies by 325.6% during the 1st quarter. AQR Capital Management LLC now owns 107,899 shares of the company’s stock valued at $150,000 after purchasing an additional 82,545 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Taysha Gene Therapies by 13.5% during the 2nd quarter. Rhumbline Advisers now owns 233,256 shares of the company’s stock valued at $539,000 after purchasing an additional 27,794 shares in the last quarter. Prudential Financial Inc. raised its holdings in shares of Taysha Gene Therapies by 50.5% during the 2nd quarter. Prudential Financial Inc. now owns 22,790 shares of the company’s stock valued at $53,000 after purchasing an additional 7,650 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Taysha Gene Therapies by 27.4% during the 2nd quarter. Invesco Ltd. now owns 203,671 shares of the company’s stock valued at $470,000 after purchasing an additional 43,772 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in shares of Taysha Gene Therapies during the 2nd quarter valued at $184,000. Institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.